OECD cuts UK growth forecasts; interest rates to remain higher for longer, Fed indicates – business live
We are pleased with the sales growth in the first three months of 2024, driven by increased demand for our GLP-1-based diabetes and obesity treatments,” Booming demand for Wegovy – which was made available in the UK last September – drove up Novo Nordisk’s share price to record levels and making it Europe’s most valuable company.